Actively Recruiting
Study of Fructose and Glucose Effects on Liver Inflammation and Metabolism in Adults Aged 45 to 65 with Metabolic Dysfunction-associated Steatohepatitis or Steatosis
Led by Queen Mary University of London · Updated on 2026-07-31
72
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Metabolic dysfunction-associated steatotic liver disease MASLD is a condition where fat accumulates in the liver, potentially leading to inflammation and damage known as metabolic dysfunction-associated steatohepatitis MASH. MASH increases the risk of severe liver scarring and liver cancer. This study aims to understand how fructose, a sugar found in fruit, honey, table sugar, and processed foods, affects metabolism and inflammation in people with MASH compared to those with MASLD or no liver disease. The trial is a four-week, randomized, double-blind study involving 36 people with MASH, 18 with MASLD, and 18 healthy controls. Participants will first follow a low-sugar diet for two weeks, receiving dietary counseling and personalized meal plans. After this run-in period, they will be randomly assigned to consume either 100 grams per day of fructose or glucose supplements, dissolved in water and taken between meals, while continuing the low-sugar diet for another 14 days. All participants will also take a daily multivitamin to prevent nutrient deficiencies. An optional sub-study will use stable isotope tracers to further measure how these sugars are metabolized. Participants will attend up to five visits including consent, screening, baseline, pre-intervention, and post-intervention. At visits 1, 2, and 3, they will provide blood, urine, stool, and saliva samples, undergo metabolic testing with a standard meal and hourly blood draws over six hours, and have body measurements taken. Researchers will measure inflammation, liver fat, metabolism, gut microbiota, and other markers to compare the effects of fructose versus glucose. Participants routine care will not change, and any significant findings will be shared with their healthcare providers.
CONDITIONS
Brief Title
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
Research Team
W
William Alazawi, MA(Cantab), MB, PhD
O
Olivia Bolton, Masters
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here